APO-LAMIVUDINE DIN 02369052
Health Canada record
| Active ingredient(s) | LAMIVUDINE 150 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AF05 LAMIVUDINE |
| Original market date | 18-May-2012 |
| Current status date | 18-May-2012 |
| Source | Health Canada DPD |
Establishment licence of the holder
Apotex Inc — licence 100375, currently licensed, last inspection rating C (2026-04-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing LAMIVUDINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02247825 | 3TC | VIIV HEALTHCARE ULC | Tablet | LAMIVUDINE 300 MG | Marketed |
| 02192691 | 3TC | VIIV HEALTHCARE ULC | Solution | LAMIVUDINE 10 MG | Marketed |
| 02192683 | 3TC | VIIV HEALTHCARE ULC | Tablet | LAMIVUDINE 150 MG | Marketed |
| 02369060 | APO-LAMIVUDINE | APOTEX INC | Tablet | LAMIVUDINE 300 MG | Marketed |
| 02393239 | APO-LAMIVUDINE HBV | APOTEX INC | Tablet | LAMIVUDINE 100 MG | Marketed |
| 02375540 | APO-LAMIVUDINE-ZIDOVUDINE | APOTEX INC | Tablet | LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG | Marketed |
| 02281368 | APO-ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE | APOTEX INC | Tablet | LAMIVUDINE 150 MG; NEVIRAPINE 200 MG; ZIDOVUDINE 300 MG | Approved |
| 02414414 | AURO-LAMIVUDINE/ZIDOVUDINE | AURO PHARMA INC | Tablet | LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG | Marketed |
| 02507129 | JAMP LAMIVUDINE | JAMP PHARMA CORPORATION | Tablet | LAMIVUDINE 300 MG | Marketed |
| 02507110 | JAMP LAMIVUDINE | JAMP PHARMA CORPORATION | Tablet | LAMIVUDINE 150 MG | Marketed |
| 02502801 | JAMP LAMIVUDINE / ZIDOVUDINE | JAMP PHARMA CORPORATION | Tablet | LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG | Marketed |
| 02512467 | JAMP LAMIVUDINE HBV | JAMP PHARMA CORPORATION | Tablet | LAMIVUDINE 100 MG | Marketed |
| 02282216 | LAMIVUDINE ORAL SOLUTION | AUROBINDO PHARMA LIMITED (UNIT III) | Solution | LAMIVUDINE 10 MG | Approved |
| 02410575 | AURO-LAMIVUDINE | AURO PHARMA INC | Tablet | LAMIVUDINE 150 MG | Cancelled Post Market |
| 02410567 | AURO-LAMIVUDINE | AURO PHARMA INC | Tablet | LAMIVUDINE 300 MG | Cancelled Post Market |
| 02239213 | COMBIVIR | VIIV HEALTHCARE ULC | Tablet | LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG | Cancelled Post Market |
| 02239193 | HEPTOVIR | GLAXOSMITHKLINE INC | Tablet | LAMIVUDINE 100 MG | Cancelled Post Market |
| 02239194 | HEPTOVIR | GLAXOSMITHKLINE INC | Solution | LAMIVUDINE 5 MG | Cancelled Post Market |
| 02387247 | TEVA-LAMIVUDINE/ZIDOVUDINE | TEVA CANADA LIMITED | Tablet | LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 25390 | 2021-03-08 | Supplement to an Abbreviated New Drug Submission (SANDS) | UPDATING THE PRODUCT MONOGRAPH |
| 18293 | 2016-07-20 | Supplement to an Abbreviated New Drug Submission (SANDS) | REVISIONS TO THE PRODUCT MONOGRAPH AND LABELS |
| 15967 | 2014-08-18 | Abbreviated New Drug Submission (ANDS) | |
| 13239 | 2012-04-27 | Abbreviated New Drug Submission (ANDS) |
International API supply for LAMIVUDINE
8 valid EDQM Certificates of Suitability from 8 holders. 24 active FDA Drug Master Files.
Request a quote for APO-LAMIVUDINE